ChemoMetec

Management Reports • Aug 15, 2022

15 August 2022

Clarification of expectations for revenue and operating profit for FY2021/22

ChemoMetec hereby clarifies the expectations for revenue and operating profit for the financial year 2021/22, which covers the period 1 July 2021 to 30 June 2022.

Based on the preliminary financial figures, ChemoMetec now expects revenue of around DKK 427 million in 2021/22, against the previously announced DKK 420-425 million. Furthermore, an operating profit (EBITDA) of around DKK 223 million is expected, against the previously announced DKK 218-221 million.

ChemoMetec expects to release the Annual Report for FY2021/22 on Thursday, 15 September 2022.

For further information

Steen Søndergaard, CEO, ChemoMetec A/S Phone: (+45) 4813 1020

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec's customers include some of the world's leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go to www.chemometec.com